<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of the infant immune system and the legacy of enhanced" exact="respiratory disease" post="(ERD) after RSV infection following immunization with formalin inactivated"/>
 <result pre="addition, RSV remains the leading cause of hospitalization due to" exact="respiratory disease" post="in infants and children under 5 years of age3."/>
 <result pre="obstacle in RSV vaccine development is the legacy of vaccine-enhanced" exact="respiratory disease" post="(ERD). In clinical trials in the 1960s, children vaccinated"/>
 <result pre="and reduced cytotoxic CD8+ T cell priming and evidence of" exact="eosinophilia" post="in the lung after RSV challenge9â€“16. The neonatal immune"/>
 <result pre="of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated" exact="hypersensitivity" post="to subsequent RSV infectionJ. Virol.200276115611156912388717 12.GrahamBSet al.Priming immunization determines"/>
 <result pre="36.TamerisMet al.A double-blind, randomised, placebo-controlled, dose-finding trial of the novel" exact="tuberculosis" post="vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated"/>
 <result pre="in West African children and infantsMol. Ther.2016241470147727109630 47.KaginaBMet al.The novel" exact="tuberculosis" post="vaccine, AERAS-402, is safe in healthy infants previously vaccinated"/>
</results>
